MANIV
4.4.2024 17:21:27 CEST | Business Wire | Press release
Maniv, a global venture capital firm based in Tel Aviv and NYC, today announces the closing of its third fund, an $140m vehicle to invest in Seed and Series A stage startups that brings the firm’s assets under management to nearly $320m.
Investing since 2016, Maniv was among the first institutional investors to articulate a global, early-stage investment strategy focused on the intersection between mobility, transportation and energy. Maniv invests in deep technologies and business model innovations around two central themes:
The movement of people and goods continues to be marked by analog processes and data-poor operating environments. From manufacturing to fulfillment and logistics, vehicle access, maintenance and repair, insurance, fleet management, and more, startups are driving the digitization of transportation’s value chains across land, sea, and air. Simultaneously, the market-driven decarbonization of transportation – representing as much as one quarter of global GHG emissions – is at an inflection point. Private sector incentives are tipping towards clean propulsion, a process accelerated by brisk regulatory tailwinds worldwide. These seismic shifts create a massive opportunity for startups to advance new technologies, form factors, business models, and platforms.
Maniv has already made four investments out of the new fund. Celadyne, based in Chicago, extends the lifespan and efficiency of proton-exchange membranes to make green hydrogen production financially viable. Neologic, based in Israel, introduces a proprietary chip design for dramatic performance and power gains in data centers, automotive and beyond. Circular, based in San Francisco, mainstreams post-consumer recycled plastics adoption in manufacturing, by closing pervasive information and testing gaps. Vammo, based in São Paulo, is electrifying LATAM’s B2B two-wheeler market, by orchestrating vehicles, financing, and a ubiquitous battery swapping network.
From its first two, top-performing funds, Maniv led investments in breakout companies including AI edge silicon scaleup Hailo from Tel Aviv, EV ridehail and charging network Revel from New York, medium-duty EV truckmaker Harbinger Motors from Los Angeles, intercity bussing platform Kolors from Mexico City, two-wheeler EV OEM River from Bangalore, and Madrid-based car subscription startup Bipi, acquired by Renault’s financing arm RCI Banque in 2021.
Maniv’s third fund is backed by institutional capital, high-net-worth individuals, and a consortium of industry leaders at the forefront of the transportation sector. Maniv’s prior funds were substantially backed by leading carmakers and Tier-1 suppliers. Maniv III maintains those automotive partnerships – including return investors Valeo and InMotion Ventures, the investment arm of Jaguar-Land Rover, joined by Woven Capital of Toyota Motor Corp. The new fund has expanded its LP base to reflect critical automotive adjacencies through partners including global vehicle leasing and mobility solutions leader Arval and the automotive finance experts of BNP Paribas Personal Finance of Europe’s leading bank BNP Paribas; Shell Ventures of the global energy giant Shell; global sustainable infrastructure leader Ferrovial; Enterprise Mobility Ventures, the VC arm of Enterprise Mobility; industrial manufacturing leader ITT Inc.; fleet payments leader WEX; a major European insurance company; several major automotive dealer and distributor groups; and more.
“Our third fund builds on two decades in the trenches of the global mobility ecosystem,” said Michael Granoff, the firm’s Managing Partner. “Maniv has built a platform to summon the best of two worlds – the agility of a traditional VC, and close proximity to the underlying industries surrounding mobility and transportation. We believe we are uniquely structured to leverage our deep institutional memory and access to industry decision-makers, for the benefit of our portfolio companies and ultimately our investors. Announcing this new vehicle amidst a backdrop of geopolitical uncertainty and shaky private markets is a testament to the resilience of the sector and our strategy.”
“Maniv’s mandate is to deliver outsized returns by joining forces with those rare entrepreneurs with both the vision and tenacity to drive the transportation sector into the 21st century,” added Nate Jaret, General Partner at Maniv. “Human prosperity depends on the seamless and sustainable movement of people and goods; mobility continues to represent a generational opportunity for entrepreneurs and investors alike.”
“When we met Maniv, we had spoken to over 100 investors and operators of electric mobility around the world and nobody – repeat nobody – was more knowledgeable about the space than the Maniv team,” said Jack Sarvary, Co-founder & CEO of portfolio company Vammo based in São Paulo. “Getting them not just onto our cap table but also our board quickly became a priority.”
"From the outset it was clear that Maniv is deeply connected to forward-thinking mobility players,” said Ian Arthurs, Founder & CEO of portfolio company Circular. “Within weeks of our first conversation, the Maniv team found us new enterprise partners and customers in the auto space, which would have taken us months to figure out on our own.”
Website: www.maniv.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404972652/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
